SiBone (SIBN)
(Delayed Data from NSDQ)
$13.60 USD
-0.02 (-0.15%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $13.61 +0.01 (0.07%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$13.60 USD
-0.02 (-0.15%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $13.61 +0.01 (0.07%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth A Momentum B VGM
Zacks News
BioSig (BSGM) Grows in Arrhythmia Care With Subscription Model
by Zacks Equity Research
BioSig's (BSGM) subscription model for PURE EP provides electrophysiologists and cardiology departments with flexibility.
Thermo Fisher's (TMO) EXTENT Solution Makes Commercial Launch
by Zacks Equity Research
Thermo Fisher (TMO) announces the commercial launch of the EXTENT Solution with IVDR certification.
Here's Why You Should Retain Tandem Diabetes (TNDM) Now
by Zacks Equity Research
Investors continue to be optimistic about Tandem Diabetes (TNDM) due to the t:slim X2 insulin pump and new product innovations.
Boston Scientific (BSX) Expands Globally Amid FX Concerns
by Zacks Equity Research
Boston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of GI and pulmonary treatment options.
CVS Health's (CVS) Cordavis to Focus on Biosimilar Products
by Zacks Equity Research
CVS Health's (CVS) wholly owned subsidiary, Cordavis, is set to bring high-quality biosimilar products to the market.
NanoString (NSTG) Advances in Xenotransplantation With New Study
by Zacks Equity Research
NanoString's (NSTG) nCounter Analysis System facilitates bulk tissue transcriptome profiling, revealing the intricacies of the immune response through the nCounter Human Organ Transplant Panel.
Myriad Genetics (MYGN) Teams Up to Assess Breast Cancer Risk
by Zacks Equity Research
Myriad Genetics (MYGN) announces collaboration with Onsite Women's Health to develop a breast cancer risk assessment program.
Align (ALGN) Rides on Growing Invisalign Sales, New Alliances
by Zacks Equity Research
Align Technology (ALGN) is expanding its sales and marketing by reaching new countries and regions.
Here's Why Investors Should Retain ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD), backed by the continued demand for digital health solutions.
Teleflex (TFX) Upgrades the Arrow ErgoPack Complete System
by Zacks Equity Research
Teleflex's (TFX) expanded Arrow ErgoPack Complete Kit now includes Hemodialysis and Large Bore catheters.
Edwards Lifesciences (EW) Rides on TAVR Amid Rise in Costs
by Zacks Equity Research
Edwards Lifesciences' (EW) Surgical Structural Heart business growth is driven by increased penetration of its premium RESILIA products across all regions.
Illumina (ILMN) Expands Presence in India With New Facility
by Zacks Equity Research
Illumina (ILMN) boosts genomic capabilities in India with a new state-of-the-art Solutions Center.
3 Reasons to Retain Intuitive Surgical (ISRG) in Your Portfolio
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.
Quest Diagnostics (DGX) Base Volume Aids Amid Low COVID Tests
by Zacks Equity Research
Quest Diagnostics (DGX) continues to witness growth momentum in the cardiometabolic, endocrinology, infectious disease and carrier and prenatal genetic screening services.
Thermo Fisher (TMO) Business Hurt by Low COVID Sales, FX Woe
by Zacks Equity Research
Thermo Fisher (TMO) is witnessing headwinds in the government and academic end markets.
Bruker (BRKR) Set to Acquire PhenomeX in an All-Cash Deal
by Zacks Equity Research
Bruker (BRKR) initiates its entry into since-cell biology research solutions with the acquisition of PhenomeX.
Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about IDEXX (IDXX) due to the CAG business and the company's execution of its growth strategy.
Myriad Genetics (MYGN) Adds ARR to Prolaris Biomarker Test
by Zacks Equity Research
Myriad Genetics (MYGN) announces the integration of ARR into the Prolaris prostate cancer prognostic test.
Syneos Health (SYNH) to Go Private, Reports Q2 Performance
by Zacks Equity Research
Syneos Health (SYNH) announces shareholders' approval for the impending merger and releases second-quarter 2023 financial results.
Will Humana (HUM) Q2 Earnings Beat on Strong Pharmacy Business?
by Zacks Equity Research
Humana's (HUM) second-quarter results are likely to reflect rising premiums and investment income.
Charles River (CRL) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Continued global demand for research models and associated services' strong DSA segment performance is likely to have driven Charles River's (CRL) Q2 revenues.
Can Conifer Weakness Affect Tenet Healthcare's (THC) Q2 Earnings?
by Zacks Equity Research
Tenet Healthcare's (THC) second-quarter results are likely to reflect higher Ambulatory Care operating revenues and supply costs.
CVRx (CVRX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
CVRx (CVRX) delivered earnings and revenue surprises of 1.75% and 10.94%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Higher Costs Affect HCA Healthcare's (HCA) Q2 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) second-quarter results are likely to reflect increased patient volumes, occupancy rate and cost of supplies.
InMode (INMD) to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
InMode (INMD) is expected to report strong Q2 consumable and service revenues, banking on strong performances of seven patented technologies across 10 product families.